Biofourmis vs Abridge
A detailed comparison to help you choose between Biofourmis and Abridge.
🏆
Verdict: Abridge wins
Abridge scores 4.2/5, edging out Biofourmis at 3.6/5. Large US health systems on Epic standardising ambient documentation across thousands of clinicians, with the integration staff and budget for a multi-year enterprise rollout.
Biofourmis AI-powered patient monitoring and clinical insights for chronic disease management | Abridge AI-powered healthcare documentation and clinical conversations | |
|---|---|---|
| Rating | 3.6 (1 review) | 4.2 (1 review) |
| Pricing Model | paid | paid |
| Starting Price | From $1000/mo | From $99/mo |
| Best For | Large health systems, IDNs and payers standing up hospital-at-home, post-acute or chronic-care monitoring programmes at scale who want FDA-cleared predictive analytics bundled with the clinical teams to act on it. | Large US health systems on Epic standardising ambient documentation across thousands of clinicians, with the integration staff and budget for a multi-year enterprise rollout. |
| Free Tier | ||
| API Access | ||
| Team Features | ||
| Open Source | ||
| Tags | ssoteam features | api accessteam featuresgdpr compliant |
| Visit Biofourmis → | Visit Abridge → |
Biofourmis
Pros
- + FDA-cleared analytics with Breakthrough Device Designation for BiovitalsHF — the strongest regulatory validation I have found in the RPM category.
- + The Biovitals engine models each patient against their own physiological baseline instead of population norms, which should meaningfully cut alert noise compared with threshold-based RPM (worth testing in any pilot).
- + It sells the escalation pathway with the software: virtual nursing, licensed navigators and in-home services (diagnostics, DME, meds, transport) orchestrated in one clinician dashboard — addressing the 2am-response gap that sinks most monitoring programmes.
- + Proven health-system deployments — AdventHealth acute care-at-home (January 2025), Lee Health hospital-at-home expansion (November 2024), plus UCI Health, Orlando Health, Augusta University Health and others named in company materials.
- + Device-agnostic sensor strategy with Epic EHR integration and a GE HealthCare partnership extending monitoring from hospital to home, so it fits existing clinical infrastructure rather than replacing it.
Cons
- - Zero commercial transparency: enterprise-only, no public pricing, custom contracts priced on patient volume and programme type — there is nothing to anchor a negotiation against.
- - The company has been through 120 layoffs (July 2023), a founder-CEO departure, an all-stock merger with CopilotIQ (October 2024) and a divestiture of its life-sciences arm (January 2025) — continuity risk on multi-year contracts.
- - Key performance claims (120+ biomarkers, deterioration detected days ahead, readmission reduction) are vendor-reported; I could not find independent head-to-head clinical evaluations.
- - No longer a clinical-trials vendor: biopharma buyers must now go to ActiGraph, which acquired Biofourmis Connect in January 2025.
- - It is a service-plus-software purchase — clinical staffing is embedded in the model, so the labour agreement carries as much delivery risk as the platform itself.
Abridge
Pros
- + Linked Evidence maps each note sentence back to the source audio moment — in my evaluation the click-through verification loop made spot-checking a note take seconds per section, the fastest trust mechanism in the category
- + Deepest Epic integration available: Abridge Inside runs across Haiku, Canto, Hyperdrive and the ASAP emergency module with bidirectional note sync and no app-switching
- + Platform expansion is coherent rather than scattershot — revenue-cycle coding documentation, nursing notes, Outpatient Orders, prior authorisation via Highmark/Availity, and NEJM/JAMA-backed decision support
- + Best in KLAS for Ambient AI in both 2025 and 2026, with named wall-to-wall deployments at Kaiser Permanente, Mayo, Johns Hopkins, Duke and UPMC
- + Financially durable: roughly $812–830M raised, a $5.3B valuation as of the April 2026 extension, and NVIDIA/Eli Lilly partnerships extending the model layer
Cons
- - Enterprise-only: no self-serve signup, no free trial, no public pricing; third-party estimates (~$2,500/clinician/year) are guesses against multi-year negotiated contracts
- - Deployment is a weeks-to-months Epic integration project — the full feature set is thinnest outside Epic environments
- - Epic is both distribution engine and competitor: the Workshop co-development program ended and Epic now ships its own native ambient scribe
- - Vendor-reported outcomes (60–86% documentation time reduction, ~55% burnout reduction) are health-system/vendor figures without independent standardised benchmarks
- - New data uses — revenue-cycle coding, trial screening with Eli Lilly — raise data-minimisation and governance questions that each health system must settle locally
Frequently Asked Questions
Which is better, Biofourmis or Abridge?▼
Abridge scores higher at 4.2/5 vs 3.6/5 for Biofourmis, making it the better-rated option in our comparison.
What is the difference between Biofourmis and Abridge?▼
Biofourmis: Biofourmis runs remote patient monitoring and care-at-home programmes, combining wearable data with clinical analytics for health systems and life-science companies. Abridge: Abridge listens to clinical conversations and produces structured notes for the medical record, used across hospital systems.
Is Biofourmis or Abridge more affordable?▼
Biofourmis starts at €1000/mo, Abridge starts at €99/mo. Check the comparison table above for current pricing.
Stay in the loop
Get weekly updates on the best new AI tools, deals, and comparisons.
No spam. Unsubscribe anytime.